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Abstract 
Background: CpG islands in hepatitis B virus (HBV) genome are potential targets for methylation mediated gene 
silencing, and may be involved in the pathogenesis of HBV infection. To date, their characteristics in HBV quasispecies 
(QS) remain largely unknown. The purpose of this study was to investigate the characteristics of CpG islands in HBV 
QS.
Methods: Forty patients diagnosed as acute hepatitis B (AHB, n = 10), immune‑tolerant HBV carriers (IT, n = 9), 
chronic hepatitis B (CHB, n = 11), or acute on chronic liver failure (ACLF, n = 10), were enrolled in this case–control 
study. A total of 599 clones were isolated, and full‑length HBV genomes were sequenced.
Results: CpG island II (CGII) in AHB group was shorter in length and its QS heterogeneity was lower than that in 
the chronic infection group. Among the chronic infection subgroups, CGII and CpG island III (CGIII) in IT group were 
longer and their heterogeneity was lower compared to CHB and ACLF groups. Length of CGII correlated with HBV 
DNA levels positively while the complexity and diversity of CGII correlated with HBV DNA levels negatively. Moreover, 
CGII and CGIII were shorter in genotype B than those in genotype C, while QS complexity and diversity of either CGII 
or CGIII had no significant difference between genotype B and C.
Conclusions: Overall, our results suggest that the distribution, length and QS heterogeneity of CpG islands in full‑
length HBV genome differ across clinical phases of infection, of which the mechanism warrants further study.
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Background
Hepatitis B virus (HBV) infection is a challenging health 
problem and a leading cause of liver diseases in Asia–
Pacific region. It is estimated that approximately 240 
million people are chronically infected worldwide, and 
are at risk of developing end-stage liver diseases (Ott 
et al. 2012). Although the molecular mechanisms deter-
mining persistent infection are not fully elucidated, it is 
generally accepted that both the virus genome and host 
immune system contribute to the outcomes of infection.
CpG islands which are CpG-rich regions in HBV 
genome, are potential targets for methylation medi-
ated gene silencing and are related with virus replication 
(Vivekanandan et al. 2010). There are three conventional 
CpG islands termed CpG island I (CGI), CpG island 
II (CGII) and CpG island III (CGIII) (Zhang et  al. 
2013). CGI (nt67  ~  nt212) is located in the start site of 
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the S region, and CGII (nt1170  ~  nt1671) overlaps the 
enhancer I and the promoter of X region, while CGIII 
(nt2280 ~ nt2455) covers the partial C gene and encom-
passes the start site of the P region. Different distribu-
tion of CpG islands which can affect their methylation 
status and HBV gene expression, might further lead to 
different clinical outcomes of HBV infection. Previous 
studies have shown that distribution of CpG islands dif-
fered across HBV genotypes (Hou et al. 2015; Zhang et al. 
2013; Zhong et al. 2015). However, all of the nucleotide 
sequences mentioned in those studies were searched 
from Genbank at the National Center for Biotechnol-
ogy Information. To date, there is no datum from real-
life study to explore the characteristics of CpG islands in 
HBV genome from different phases of infection.
It is worth noting that HBV exists as a spectrum of 
strains. Due to a high replication rate and lack of proof-
reading activity during reverse transcription, HBV exists 
as quasispecies (QS), including variants which are geneti-
cally distinct, but closely related (Ngui and Teo 1997). 
Because of the different adaptability, QS are related to 
the outcome of HBV infection (Cao et al. 2014; Yang et al. 
2015) and antiviral response (Liu et al. 2011; Chen et al. 
2009; Cheng et  al. 2013; Peveling-Oberhag et  al. 2013; 
Tong et al. 2013). Collectively, the characteristics of CpG 
islands in HBV QS isolated from real-life patients remain 
largely unknown.
In the present study, 599 clones from forty patients 
were isolated, and full-length HBV genomes were 
sequenced. Characteristics of CpG islands, including the 
distribution, length and heterogeneity in HBV QS, were 




Forty treatment-naïve patients with HBV infection from 
Shanghai Ruijin Hospital were retrospectively enrolled 
in our present study. These patients were enrolled from 
September, 2009 to January, 2014. Among 40 patients, 
10 patients were diagnosed as acute hepatitis B (AHB), 
9 patients in high replicative, low inflammatory phase 
(previously termed “immune-tolerant HBV carriers”, 
IT) (Gish et al. 2015), 11 patients with chronic hepatitis 
B (CHB), and the other 10 with acute on chronic liver 
failure (ACLF). AHB is defined as a transient presence 
of HBsAg within 6  months without previous history of 
chronic hepatitis B. Diagnosis of IT, CHB and ACLF was 
according to criteria recommended by the Asian Pacific 
Association for the Study of the Liver (APASL) (Sarin 
et  al. 2009; Liaw et  al. 2012). IT is defined as HBeAg 
positive with high levels of HBV DNA (>2,000,000  IU/
ml) but have normal serum alanine aminotransferase 
(ALT) (Liaw et al. 2012), while inclusion criteria of CHB 
group are HBsAg positive for more than 6  months and 
HBV DNA level >20,000  IU/ml with serum ALT level 
more than 2 ULN, in the present study (Yang et al. 2015). 
ACLF was defined as an acute hepatic insult manifesting 
as jaundice, coagulopathy, complicated within 4 weeks by 
ascites and/or encephalopathy in patients with previously 
diagnosed chronic HBV infection (Sarin et  al. 2009). 
Sera of AHB and ACLF patients were collected during 
the first week of clinical onset. Patients were excluded if 
they were diagnosed as autoimmune liver disease, alco-
holic liver disease, or co-infection, such as human immu-
nodeficiency virus, hepatitis C virus, hepatitis D virus, 
Epstein-Barr virus, cytomegalovirus. Sera were collected 
from clinical detecting laboratory after completing clini-
cal tests. The remaining sera were collected and froze in 
−80 °C refrigerator.
Compliance with ethical standards
The study was a non-invasive and non-interventional ret-
rospective study. The study was fully anonymous, thus it 
cannot do harm to the patients. The study was approved 
by the Ethics Committee of Ruijin Hospital in accordance 
with the Declaration of Helsinki.
Liver biochemistry, HBV serological markers and HBV DNA 
tests
Liver biochemistry indexes were tested using an auto-
mated chemistry analysis system (Beckman Coulter, 
Fullerton, CA, USA). HBV serological markers including 
HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc were 
determined by chemiluminescent microparticle enzyme 
immunoassay using the Abbot Architect immunoassay 
system (Abbort Laboratories, Abbott Park, IL, USA). The 
HBV DNA levels were measured by PCR using the Cobas 
Amplicor HBV Monitor Test (Roche Diagnostics, Man-
nheim, Germany) with a low detection limit of 60 IU/ml.
Molecular cloning and sequencing
As described in our previous study (Yang et  al. 2015), 
HBV DNA was extracted from 200 μl serum at baseline 
(before treatment) using the QIAamp blood mini-kit 
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The full-length HBV genomes were 
amplified by PCR as Gunther described (Gunther et  al. 
1995). The primers were as follows: 5′-TTT TTC ACC 
TCT GCC TAA TCA-3′ (forward, nt 1821–1841) and 
5′-AAA AAG TTG CAT GGT GCT GG-3′ (reverse, nt 
1825–1806). PCR products of about 3200 bp were puri-
fied using the QIAquick Gel Extraction Kit (QIAgen 
Hilden, Germany), and cloned into the pGEM-T vector 
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after the addition of adenylate-tail (Promega, Madison, 
WI, USA), and then transformed into TOP10 Escherichia 
coli competent cells (Invitrogen, Carlsbad, CA) growing 
on ampicillin plates. An average of 15 (range from 14 to 
17) positive clones per sample were sequenced using an 
ABI 3730 automated sequencer (Applied Biosystems, 
Foster City, CA, USA). A total of 599 clones from 40 
patients were sequenced.
QS heterogeneity analysis
All sequences were aligned using CLUSTAL X (version 
2.0 (Thompson et  al. 1997); RDP3 software was used 
to detect recombinant sequences which were excluded 
(Martin and Rybicki 2000; Liu et al. 2011). Sequence seg-
ments were assembled to full-length HBV using Codon 
Code Aligner 3.7.1 software package (Codon Code Cor-
poration, Dedham, MA). Genotypes of each sequence 
were determined using the HBV STAR program 
online(Myers et  al. 2006). Viral QS heterogeneity was 
evaluated with complexity and diversity. QS complexity 
refers to the distribution of different mutant genomes 
in a population, and it is calculated using normalized 
Shannon entropy (Sn) formula as previously described 
(Liu et al. 2011; Domingo et al. 2006; Chen et al. 2009). 
QS diversity was defined as the relatedness of individu-
als within the population, and it was evaluated by the 
mean genetic distance (d, 10−3  subsituation/site) using 
MEGA5.0 software (Tamura. 1992; Tamura et al. 2007).
CpG islands analysis
CpG islands were analyzed using the MethPrimer (http://
www.urogene.org/cgi-bin/methprimer/methprimer.
cgi) and the CpG Plot (http://www.ebi.ac.uk/Tools/
emboss/cpgplot). The CpG islands were defined accord-
ing to three criteria (Fazzari and Greally 2004; Zhang 
et al. 2013): (1) a GC content of ≥50 %, (2) an observed-
to-expected CpG dinucleotide ratio ≥0.60, and (3) a 
sequence longer than 100  bp. The distribution, length, 
and QS heterogeneity of CpG islands within each clone 
were obtained.
Statistical analysis
Length and QS complexity of CpG islands were 
expressed as mean  ±  SE, while the mean genetic dis-
tance was expressed as median with range. Results of 
continuous variables were compared between acute and 
chronic infection groups by unpaired t test or the Mann–
Whitney test, and variables were compared between the 
chronic subgroups by one-way ANOVA analysis of vari-
ance or Kruskal–Wallis test as needed. Proportion of 
diseases was compared using Chi Square tests. Correla-
tions were analyzed using Pearson correlation analysis. 
All analyses were performed using SPSS19.0 software 
(Chicago, IL, USA). Differences were considered signifi-
cant at a P value <0.05.
Results
Clinical and laboratory data of patients
The demographics, clinical and laboratory data are 
shown in Table  1. All AHB patients had spontaneous 
HBsAg/anti-HBs seroconversion, and five in ten ACLF 
patients died within 3 months after the clinical onset of 
infection. The proportions of patients harboring HBV 
genotype B and C did not differ significantly among the 
four groups (P > 0.05).
Distribution of CpG islands in patients with different 
phases of infection
Experiments of molecular cloning and sequencing were 
performed in our previous study (Yang et al. 2015), and 
the characteristics of CpG islands in full-length HBV 
genomes of 599 clones were analyzed and new data 
were generated in the present study (Genbank submis-
sion numbers: KU963799–KU964397). The distribution 
of CpG islands in HBV-related liver diseases is shown 
in Fig. 1. All clones contained CGII and CGIII. Besides 
the three conventional CpG islands, CpG island IV 
(CGIV, nt332  ~  nt632) was identified. The frequency 
of strains containing CGIV in AHB, IT, CHB and 
ACLF group was 0 % (0/146), 11.19 % (15/134), 9.09 % 
(15/165) and 28.57 % (44/154), respectively. Strikingly, 
CGIV was much more common in ACLF group, com-
pared to the other three groups (χ2 =  59.76, P < 0.01) 
(Fig. 1b).
QS characteristics of CpG islands in patients with acute 
and chronic infection
In an attempt to investigate the characteristics of CpG 
islands among different phases of infection, lengths and 
QS heterogeneity of CpG islands were compared (data 
shown in the Additional file  1: Table S1). As shown 
in Fig.  2a, length of CGII in AHB group was statisti-
cally shorter than that in the chronic infection group 
(P < 0.01). QS complexity and diversity of CGII in AHB 
group were lower than those in the chronic infection 
group (P < 0.01).
As for CGIII, there was no significant difference in 
length between acute and chronic infection groups. Simi-
lar to CGII, complexity and diversity of CGIII in AHB 
group were lower than those in the chronic infection 
group (P < 0.01) (Fig. 2b).
QS characteristics of CpG islands in patients with chronic 
infection
Comparison of QS characteristics among chronic infec-
tion subgroups is shown in Fig. 3. Among the subgroups, 
Page 4 of 10Xue et al. SpringerPlus  (2016) 5:1630 
IT patients had longer CGII than CHB and ACLF patients. 
Compared to CHB and ACLF subgroups, QS complexity 
of CGII in IT subgroup was lower. As for QS diversity, it 
was lower in IT subgroup than that in ACLF subgroup.
Similar to CGII, CGIII in IT subgroup was the longest, 
and its QS heterogeneity was the lowest, while there was no 
significant difference between CHB and ACLF subgroups.
HBV DNA levels correlate with the length and QS 
heterogeneity of CpG island II
Pearson correlation analysis revealed a positive correla-
tion between HBV DNA levels and the length of CGII 
(r  =  4.66, P  <  0.01), while HBV DNA levels correlated 
negatively with QS complexity (r = −4.54, P < 0.05) and 
diversity (r = −4.31, P < 0.05) of CGII (Fig. 4).
Table 1 Demographic and clinical features of patients (mean ± SE)
The proportions of patients harboring HBV genotype B and C did not differ significantly among the four groups (P > 0.05)
AHB acute hepatitis B, IT immune-tolerance, CHB chronic hepatitis B, ACLF acute on chronic liver failure, ALT alanine aminotransferase, TBIL total bilirubin, PTA 
prothrombin time activity
a P < 0.01 IT versus AHB, bP < 0.01 IT versus ACLF, cP < 0.01 CHB versus AHB, dP < 0.01 CHB versus ACLF, eP < 0.01 AHB versus ACLF
AHB (n = 10) IT (n = 9) CHB (n = 11) ACLF (n = 10) P value
Sex (M/F) 9/1 5/4 6/5 10/0 0.032
Age (year) 40.70 ± 2.62 28.56 ± 1.84a,b 35.55 ± 3.89 43.80 ± 2.82 0.008
ALT (U/L) 1608.5 ± 199.29 29.67 ± 3.76a,b 263.45 ± 131.04c,d 1171.57 ± 184.49 0.001
TBIL (μmol/L) 327.62 ± 130.01 16.01 ± 1.40a,b 32.95 ± 9.36c,d 301.79 ± 29.83 0.002
PTA (%) 77.89 ± 5.45 103.33 ± 3.33 98.79 ± 1.21 30.58 ± 2.65b,d,e 0.000
HBeAg (±) 10/0 9/0 10/1 2/8b,d,e 0.000
HBV DNA (log10IU/ml) 6.55 ± 0.45 8.02 ± 0.19a,b 7.09 ± 0.38 6.34 ± 0.26 0.011
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Fig. 1 Distribution of CpG islands in HBV genome. a The vertical axes indicate the GC percentage, and the horizontal axes represent the HBV 
nucleotide sequence. The blue areas refer to the CpG islands, while the vertical red lines under the horizontal axes represent CpG dinucleotides. The 
horizontal arrows represent the open reading frames of preS1/preS2/S, X, preC/C and p genes, while the vertical arrow indicates the split CGII. CGI, 
CGII and CGIII coexist in the first graph, while CGI is absent in the second graph, and CGIV is present in the third graph. b The frequency of strains 
containing CGIV in AHB, IT, CHB and ACLF group was compared by Chi Square test. CGIV was much more common in ACLF group compared to the 
other three groups (χ2 = 59.76, P < 0.01)
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QS characteristics of CpG islands in HBV genotype B and C
Consistent with the previous studies (Zhang et al. 2013; 
Zhong et al. 2015; Hou et al. 2015), CGI and split CGII 
were much more common in HBV genotype B com-
pared to genotype C. Nevertheless, 30 clones in genotype 
C from two patients (one CHB patient and one ACLF 
patient) contained CGI, while among the 16 clones in 
genotype B from a CHB patient, only three clones con-
tained CGI.
As shown in Fig. 5, both CGII and CGIII in HBV geno-
type B were shorter than those in genotype C (P = 0.000 





















































































Fig. 2 QS characteristics of CpG islands in patients with acute and chronic infection. a CGII in AHB group was statistically shorter in length, and its 
QS complexity and diversity were lower than those in the chronic infection group. b QS complexity and diversity of CGIII were lower in AHB group 
than those in the chronic infection group
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of either CGII or CGIII had no significant difference 
between genotype B and C (P  >  0.05). Pearson correla-
tion analysis showed that QS complexity did not corre-
late with the length of CpG islands (P > 0.05).
Discussion
In the present study, characteristics of CpG islands in 
HBV QS were investigated in real-life study for the first 
time. The results indicated that CGII in AHB group was 
shorter in length and its QS heterogeneity was lower than 
that in the chronic infection group. Among the chronic 
infection subgroups, CGII and CGIII in IT subgroup 
were longer and their heterogeneity was lower compared 
to CHB and ACLF subgroups. Moreover, HBV DNA lev-
els correlated positively with the length of CGII, and neg-
atively with the heterogeneity of CGII.
The full-length HBV sequence is needed for CpG 
islands analysis. The sequence obtained by splicing 
various PCR-amplified fragments, maybe is not a real 
existing full-length sequence because of the HBV QS. 
The classic method reported by Gunther et  al. (1995) 
is still the gold standard for complete HBV genome 
study. In accordance with Gunther, all HBV strains in 
our present study were obtained by full-length cloning/

















































































Fig. 3 QS characteristics of CpG islands in patients with chronic infection. Length of CGII (a) and CGIII (b) were longer and QS complexity was lower 
in IT subgroup compared to the CHB and ACLF subgroups
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For the first time, we compared the QS characteristics 
of CpG islands from patients with different outcomes 
of infection. It is generally considered that patients 
with acute self-limited infection have effective immune 
response to eliminate virus, while immune-tolerant 
patients have high levels of HBV replication and lack 
inflammation in the liver. The mechanisms of different 
outcomes caused by HBV infection are considered to be 
multi-factorial, including the immune suppression and 
virus factors (Cao et  al. 2014). In the present study, QS 
complexity of CGII in CHB and ACLF groups was higher 
than that in IT groups. HBV QS evolution from immune-
tolerance to immune-active phases may result from the 
immune selection.
CGII which overlaps the enhancer I and the X gene 
promoter, is an important region for the regulation of 
HBV transcription and replication (Guo et  al. 2011). It 
has been reported that HBV core protein (HBc) binds 
to HBV cccDNA preferentially at the CGII region (Guo 
et  al. 2011). The frequency of HBc binding to CGII is 
positively correlated with the ratio of relaxed circular 
DNA to cccDNA and the levels of serum HBV DNA 
(Guo et al. 2011). Another study reported that promot-
ers with long CpG islands encoded more RNA polymer-
ase II binding sites than that with short ones (Elango and 
Yi 2011). CGII in AHB group is shorter than that in the 
chronically infected group, and is longer in IT subgroup 
compared to CHB and ACLF subgroups. An interesting 
finding of our study is that HBV DNA levels correlate 
positively with the length of CGII, and negatively with 
the complexity of CGII. CGII, whose length is related 
to viral replication, may play a role in the clinical out-
comes of HBV infection. Our study can partially eluci-
date mechanisms underlying the different outcomes of 
HBV infection.
Genotype B and C, which are two major prevalent 
HBV genotypes in China (Zeng et al. 2005; Chu and Liaw 
2005), have a divergence of more than 8  % in the com-
plete genome nucleotide sequence, and different clinical 
characteristics. In general, infection with HBV genotype 
B is apt to have HBV e antigen seroconversion, while 
infection with genotype C is associated with higher risk 
of developing cirrhosis and HCC compared to geno-
type B (Chu and Liaw 2005; Kong et al. 2014; Tseng and 
Kao 2008; Malmstrom et  al. 2012). To date, the mecha-
nism for the differences remains unclear. Our present 
study showed that CGI was more common and lengths 
of CGII were shorter in genotype B compared to geno-
type C. Since CGI overlaps the forepart of S gene, the 
different distribution of CGI between genotype B and C 
may affect the methylation of CpG islands, and influence 
the regulation of HBV gene expression, especially the S 
gene. Although the function of CGI remains unclear, its 
absence might induce less methylation of the first CpG-
rich region in HBV genotype C (Zhang et al. 2013), and 
likely to be associated with the progressive liver diseases 
caused by HBV genotype C. To note, as shown in the 
present study, 30 clones in genotype C from two patients 
(one CHB patient and one ACLF patient) contained CGI, 
while among the 16 clones in genotype B from a CHB 
patient, only three clones contained CGI. Different from 
the previous studies (Hou et al. 2015; Zhang et al. 2013; 
Zhong et al. 2015), data from HBV quasispecies empha-
size that, distribution of CpG islands does not abide by 
genotypes strictly.
Moreover, little is known about whether HBV geno-
types affect the QS heterogeneity. Data from this real-life 
study showed that QS complexity and diversity of either 
CGII or CGIII had no significant difference between 





















































Fig. 4 HBVDNA levels correlate with the length and QS heterogeneity of CpG island II. HBV DNA levels correlated positively with the length of CGII, 
and negatively with QS complexity and diversity of CGII
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account for the different clinical outcomes between gen-
otype B and C.
Conclusions
To our knowledge, this is the first real-life study that 
explored the QS characteristics of CpG islands in full-
length HBV genome. Obtained data demonstrate that 
lengths and QS heterogeneity of CpG islands differ 
across clinical phases of infection. These data may par-
tially explain the different clinical characteristics among 
clinical phases of infection, of which the mechanism war-
rants further study.
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Fig. 5 QS characteristics of CpG islands in HBV genotype B and C. CGII (a) and CGIII (b) in genotype B were statistically shorter than those in genotype 
C, while QS complexity and diversity of either CGII or CGIII had no significant difference between genotype B and C
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